AegirBio has received formal approval from the Notified Body on its request to prolong the shelf life of its Covid-19 antigen test. The approval is based on real-time stability data showing that the product can be stored for 24 months with the same performance. This means that the current stock of a little over 1 million tests now has a shelf life until summer 2023.
"The prolonged stability gives us time to continue working on established and new contacts in areas we know are sensitive to outbreaks due to low vaccination as well as expand direct sales by using existing and new sales channels,” says Dr Bradley Messmer, CEO of AegirBio
This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-10-2022 16:58 CET.
AegirBio is a Swedish diagnostics company that was founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results.
Certified Adviser is Eminova Fondkomission AB | +46 8-684 211 10 | email@example.com